2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

939 Real-world effectiveness of anticoagulation versus aspirin for venous thromboembolism prophylaxis in patients with multiple myeloma receiving lenalidomide: A multivariable and landmark survival analysis

Jeet Patel, DO, Evguenia Bhurtel, MD2, Al-Ola Abdallah, MD3, Jeries Kort, MD4
1 The University of Kansas Cancer Center, Kansas City, Kansas, United States, The University of Kansas Medical Center, Olathe, Kansas, United States
2 The University of Kansas Cancer Center, Kansas City, Kansas, United States
3 The University of Kansas Cancer Center, Kansas City, Kansas, United States
4 The University of Kansas Cancer Center, Kansas City, Kansas, United States

Background: Immunomodulatory drugs (IMiDs), such as lenalidomide, are a cornerstone of multiple myeloma (MM) therapy but carry a substantially increased risk of venous thromboembolism (VTE). Without prophylaxis, lenalidomide-based regimens carry a VTE risk of approximately 14%; despite prophylaxis, contemporary regimens retain a residual VTE risk of 7–13% (GRIFFIN, Myeloma XI, MELISSE). While guidelines recommend risk-adapted VTE prophylaxis using aspirin (ASA) or therapeutic anticoagulation (AC), real-world evidence comparing their effectiveness across baseline disease stages, cytogenetic risk profiles, and duration of therapy is limited. In addition, whether the relative benefit of AC changes during extended lenalidomide therapy remains unclear.

Methods: We conducted a retrospective single-center cohort study of patients with MM diagnosed between January 2020 and February 2026 who were initiated on lenalidomide-based therapy. The primary outcome was breakthrough VTE (deep vein thrombosis or pulmonary embolism) during IMiD treatment. Baseline characteristics including demographic factors, disease isotype, R-ISS stage, high-risk cytogenetics [del(17p), t(4;14), t(14;16)], renal function, initial lenalidomide dose, history of prior VTE, and IMPEDE-VTE risk scores were compared between the ASA and AC cohorts. A multivariable Cox proportional-hazards regression model was used to estimate the adjusted hazard ratio for AC versus ASA. A sub-analysis was performed comparing low-dose (81 mg) versus standard-dose (325 mg) aspirin regimens in the ASA cohort. To evaluate the temporal efficacy of thromboprophylaxis while minimizing immortal time bias, 6-month and 12-month landmark analyses were conducted among patients who remained event-free at each landmark.

Results: Among the 474 patients evaluated, 286 received ASA, and 188 received AC. Reflecting selective use in higher-risk patients, the AC group carried a heavier baseline risk burden across several domains: greater mean age (68.3 vs. 65.7 years; p=0.012), R-ISS Stage III disease (19.7% vs. 10.8%; p=0.027), high-risk cytogenetics (23.9% vs. 16.8%; p=0.049), mean IMPEDE-VTE score (4.4 vs. 3.9; p=0.024), and prior VTE (13.3% vs. 2.1%; p<0.0001).

Over 738.6 person-years (PY) of follow-up (median lenalidomide exposure 13.4 months [IQR 24.3]), 55 breakthrough VTE events occurred (43 in ASA, 12 in AC), with an overall incidence rate of 7.45 per 100 PY (9.05 in ASA vs. 4.55 in AC; incidence rate ratio 1.99, 95% CI: 1.05–3.77; p=0.035). In the primary multivariable Cox model, AC was associated with a statistically significant reduction in the hazard of VTE compared with ASA (aHR=0.31, 95% CI: 0.15–0.65; p=0.002). The IMPEDE-VTE score was an independent predictor of VTE, with each 1-point increase associated with a 2.6-fold higher hazard (aHR=2.60 per 1-point increase; p<0.0001).

Within the ASA cohort (N=283 with documented dosing), breakthrough VTE occurred in 17.4% (19/109) of patients receiving 81 mg ASA daily versus 13.8% (24/174) of patients receiving 325 mg ASA daily. In unadjusted and multivariable analyses controlling for the IMPEDE-VTE score, there was no significant difference in breakthrough VTE risk between 325 mg and 81 mg daily (HR=0.73, 95% CI: 0.40–1.33, p=0.304; aHR=1.03, p=0.947).

At the 6-month landmark, AC remained associated with a numerically lower VTE hazard, although the association did not reach statistical significance (aHR=0.34, 95% CI: 0.11–1.04; p=0.059). Among patients who remained event-free through 12 months, the treatment effect was attenuated, and the confidence interval widened (aHR=0.76, 95% CI: 0.22–2.61; p=0.658).

Conclusion: Despite being preferentially prescribed to higher-risk patients, anticoagulation was independently associated with a 69% lower hazard of breakthrough VTE than aspirin during lenalidomide therapy. Standard-dose aspirin (325 mg) offered no additional protection over low-dose aspirin (81 mg). Landmark analyses suggested that the benefit of anticoagulation was concentrated in the first 6–12 months and diminished thereafter, raising the possibility of a time-limited window in which intensive thromboprophylaxis is most valuable. These findings support risk-adapted, time-dependent thromboprophylaxis and warrant prospective evaluation in long-term lenalidomide-treated patients.

Jeet Patel, DO: No relevant conflicts of interest to declare.